Advertisement

Topics

Chiasma (Israel), LTD Company Profile

09:11 EST 11th December 2018 | BioPortfolio

Chiasma develops new drug products based on its proprietary Transient Permeability Enhancer (TPE) technology, which enables oral delivery of macromolecules (up-to 20 kDa) and poorly-absorbed small molecules into the GI wall, portal system and then to the systemic circulation. Chiasma creates its internal pipeline by selecting approved macromolecules that are currently available in injectable form, changing the route of administration to oral and evaluating them for new indications, thereby creating new drugs that will take advantage of the 505(b)(2) regulatory route in the US and similar regulations in other countries.

Chiasma’s lead candidate, Octreolin™, is a product in capsule form (administered orally) that contains octreotide acetate, a 1.0 kDa peptide in the TPE formulation. Octreolin has successfully completed a Phase I clinical study evaluating its safety and pharmacokinetics (PK). Octreolin demonstrated a PK profile similar to that of subcutaneously injected octreotide acetate. In addition, no serious adverse safety events were reported. Chiasma intends to begin a pivotal trial by the end of 2010 for acromegaly, a hormonal disorder that results from an excess of growth hormone (GH). The pool of patients eligible for Octreolin treatment is estimated to be between 10,000 and 15,000 in the US and an equal number in Europe.

Octreolin is also being developed as an oral treatment for patients with Portal Hypertension (PHT); no drugs are approved for PHT in the US. A Phase 2 trial for this new indication is expected to start in December of 2010.

The Company is also developing: (1) An oral peptide (switch from injectable) for a new CNS indication; and (2) An oral protein (switch from injectable) for a viral disease that may also result in improvements to the label.

Location

POB 45182
10 Hartom Street
Jerusalem
91450
Israel

Contact

Phone: 972-2-571-5885
Fax: 972-2-571-5886
Email: dana@chiasmapharma.com


News Articles [231 Associated News Articles listed on BioPortfolio]

Chiasma completes enrolment in Phase lll trial of octreotide

Chiasma has completed patient enrolment in its Phase lll CHIASMA OPTIMAL clinical trial evaluating octreotide capsules for the treatment of...Read More... The post Chiasma completes enrolment in Phase...

Chiasma ends enrolment in MPOWERED trial for acromegaly

Chiasma has completed patient enrolment in the MPOWERED trial, a Phase lll clinical study of octreotide capsules to treat patients...Read More... The post Chiasma ends enrolment in MPOWERED trial for ...

$CHMA Completes Enrollment of CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly. Topline data now expected in September 2019, versus prior guidance of 4Q 2019

$CHMA Completes Enrollment of CHIASMA OPTIMAL Phase 3 Clinical Trial of Octreotide Capsules in Patients with Acromegaly. Topline data now expected in September 2019, versus prior guidance of 4Q 2019

Cellcom Israel Schedules Second Quarter 2018 Results Release for August 16, 2018

NETANYA, Israel, July 29, 2018 /PRNewswire/ -- Cellcom Israel Ltd. (NYSE: CEL) (TASE: CEL) (hereinafter: the "Company"), announced today that it will be releasing its Read more...

DNA analysis of 6,500-year-old human remains in Israel points to origin of ancient culture

(American Friends of Tel Aviv University) An international team of researchers from Tel Aviv University, the Israel Antiquities Authority and Harvard University has discovered that waves of migration ...

Alvit LCS Pharma: Manufacturing and licensing agreement with the Israel's largest Medical Cannabis Company Bazelet

TEL AVIV, Israel - October 24, 2018 (Investorideas.com Newswire) Israel's largest medical cannabis company Bazelet signed a manufacturing and licensing agreement with Israeli medical cannabis pharmace...

Philips: EPD R&D staff will stay in Israel

Philips has told "Globes" that Caesarea based EPD, which it acquired for up to $530 million including milestone payments, will remain in Israel.

Medtronic execs visit recently acquired companies in Israel

A delegation of Medtronic executives, headed by Chairman and CEO Omar Ishrak, is visiting Israel to become more familiar with -More- 

PubMed Articles [118 Associated PubMed Articles listed on BioPortfolio]

Treatment Seeking for Posttraumatic Stress in Israel Defense Forces Veterans Deployed in the 2006 Israel-Hezbollah War: A 7-Year Post-War Follow-Up.

To determine the long-term prevalence of combat-related treatment seeking for PTSD in Israel Defense Force (IDF) veterans deployed to war.

Socioeconomic inequalities in exposure to environmental tobacco smoke in children in Israel.

Environmental tobacco smoke (ETS) exposure in infants and children causes more frequent and severe asthma attacks, respiratory infections, ear infections, and sudden infant death syndrome. The aim of ...

Demographic and Clinical Features of Pediatric Uveitis in Israel.

To report the epidemiology, etiology, ocular characteristics, treatment and visual outcome of pediatric uveitis in Israel.

High Endemicity and Distinct Phylogenetic Characteristics of Sindbis Virus in Israel.

Sindbis virus (SINV) is a mosquito-borne Alphavirus responsible for outbreaks of SINV disease, mainly in north Europe. SINV has been isolated from mosquitoes in Israel since the 1980s but SINV disease...

Sexual intermingling of arab and jewish men who have sex with men in israel: results of a molecular epidemiology study.

Men who have sex with men (MSM) comprise ∼30% of new HIV infections in Israel, a country with mixed Jewish and Arab populations. We molecularly characterized HIV-1 in the Arab and Jewish MSM (AMSM, ...

Clinical Trials [150 Associated Clinical Trials listed on BioPortfolio]

Characteristics of Hgb C Carriers in Northern Israel and Clinical Features Among Hgb Homozygous

Hgb C is an hemoglobinopathy quite rare in Israel. The clinical status of patients that are diagnosed as homozygous to this disease is quite benign but not study in large groups. Also the...

Israeli Multi Ethnic Centenarian Project

This study will systematically assess epigenome methylation changes in participants of the Israel multi-ethnic centenarian study cohort, which includes citizens of Israel aged 95 years and...

Epidemiology of Ulcerative Colitis and Crohn's Disease in Non Jewish Israel Population

The aim of the present study was to describe the incidence and prevalence of IBD in non Jewish Israel population

Sickle Cell Anemia in an Arab Bedouin Village in the Northern Israel

Sickle cell anemia and sickle cell thalassemia are frequent diseases among the israeli arab population. The purpose of this study is to assess the clinical characteristics of the patients ...

Group B Streptococcal Carrier State Prevalence Among Arab Pregnant Women in Northern Israel District

The incidence of early neonatal GBS (group B Streptococcus) infection in the Nazareth Hospital through the years 2006-2013 has been higher compared to the national average. On reviewing al...

Companies [250 Associated Companies listed on BioPortfolio]

Chiasma (Israel), LTD

Chiasma develops new drug products based on its proprietary Transient Permeability Enhancer (TPE) technology, which enables oral delivery of macromolecules (up-to 20 kDa) and poorly-absorbed small mol...

Chiasma, Inc.

ILSI Biomed Israel 2011

The ILSI Biomed Israel 2011 is the central annual event of Israel's life science industry. It consists of an international professional conference, targeted at the best experts an...

EpiSafe Medical Devices Ltd

EpiSafe is a privately held medical device company dedicated to the development and manufacture of medical devices for the oral cavity. It was founded in 2002 by Eran Lavi, who serves as CEO of the co...

IATI-BioMed Conference

IATI, run by CEO Karin Mayer Rubinstein is the largest umbrella organization representing the hi-tech and life sciences industries. With over 450 members, its mission is to streng...

More Information about "Chiasma (Israel), LTD" on BioPortfolio

We have published hundreds of Chiasma (Israel), LTD news stories on BioPortfolio along with dozens of Chiasma (Israel), LTD Clinical Trials and PubMed Articles about Chiasma (Israel), LTD for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Chiasma (Israel), LTD Companies in our database. You can also find out about relevant Chiasma (Israel), LTD Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Endocrinology
Diabetes Diabetes Endocrine Obesity Oxycontin Renal Disease Thyroid Disorders Endocrinology is the study of the endocrine glands and the hormones that they secrete (Oxford Medical Dictionary). There are several groups of h...


Corporate Database Quicklinks



Searches Linking to this Company Record